Abstract
Regenerative cell medicine will change the way the medical community treats disease but the legal framework necessary to encourage development and commercialization of these revolutionary therapies remains uncertain. Although strong intellectual property protection is needed to provide an incentive to undergo the rigorous regulatory scrutiny required to bring regenerative cell therapies to market, concerns over the ability to protect technologies that may be viewed as contrary to public morality or that utilize known cell populations in previously unknown ways continues to stifle investment and commercial development. The legal hurdles facing investigators, clinicians, and entrepreneurs in this rapidly developing field were discussed on March 27, 2013, at the Strategic Forum Panel Discussion on Intellectual Property held at the Stem Cell and Regenerative Medicine Global Congress 2013 in Seoul Korea. Panel Moderator Byung Hyune Choi (GSRAC) presented a series of questions to spark the discussion, and panelists, Jae Sik Choi (Korea Institute of Intellectual Property), Soon-Woong Kim (JungJin Intellectual Property Law firm), Hyojin Lee (Korean Intellectual Property Office) and I, sought to guide the audience through the global legal uncertainty facing the field of regenerative cell medicine today.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
